ATS907 is a novel ROCK inhibitor that has entered into clinical evaluation in patients in the United
States. The first in human study is a two-stage, randomized, investigator-masked, dose-ranging, safety and
efficacy study in subjects with primary open angle glaucoma and or ocular hypertension. This study is
intended to evaluate a number of different concentrations of ATS907 ophthalmic formulation and to provide
preliminary information on safety, tolerability, and efficacy (reduction in IOP). For more information on the
clinical studies please see www.clinicaltrials.gov.